Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show
|Articles|October 16, 2015
Promising Experimental MS Drugs Highlight Specialty Pharmacy Week in Review
Author(s)Davy James, Managing Editor
Top stories of the week on Specialty Pharmacy Times.
Advertisement
[<a href="//storify.com/pharmacytimes/promising-experimental-ms-drugs-highlight-specialt" target="_blank">View the story "Promising Experimental MS Drugs Highlight Specialty Pharmacy Week in Review" on Storify</a>]
Advertisement
Related to this article
Pharmacy Times featured experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Kidney Week 2026 posters show low-density lipoprotein cholesterol (LDL-C) fell by half in patients receiving dialysis, and oral enlicitide needed no dose adjustment for renal impairment.
Specialty pharmacy liaisons improve breast cancer care by easing access barriers, managing side effects, boosting adherence, and navigating new therapies and policies.
Walgreens adds virtual coverage navigation, Medicare GLP-1 Bridge support, and pharmacist follow-up calls as GLP-1 discontinuation remains high.
Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
A helpful guide for pharmacists if teas, supplements, or cultural foods are part of a patient's regular routine.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Cystatin C and the Future of Kidney Function Assessment
2
Walgreens Adds Pharmacist Outreach, Coverage Help for GLP-1s
3
GLP-1 RAs Tied to Lower Kidney Failure Risk in Patients With Obesity, CKD
4
Ribociclib Shows Overall Survival Benefit at 6 Years in NATALEE Breast Cancer Trial
5